Search Results - "Flasar, Mark H."

Step up versus early biologic therapy for Crohn's disease in clinical practice by Ghazi, Leyla J, Patil, Seema A, Rustgi, Ankur, Flasar, Mark H, Razeghi, Sanam, Cross, Raymond K

“…Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in…”
Get full text

Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients by Syed, Ali, Cross, Raymond K, Flasar, Mark H

“…Anti-tumor necrosis factor (anti-TNF) therapy effects on postoperative complications in Crohn's disease (CD) patients are unclear. We examined a retrospective…”
Get full text

Endoscopic ferromagnetic object retrieval by use of a simple magnet (with video) by Aslinia, Florence M., MD, MS, Flasar, Mark H., MD, MS

Get full text

Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir by Vaithianathan, Soundarya, Haidar, Sam H, Zhang, Xinyuan, Jiang, Wenlei, Avon, Christopher, Dowling, Thomas C, Shao, Changxing, Kane, Maureen, Hoag, Stephen W, Flasar, Mark H, Ting, Tricia Y, Polli, James E

“…The objective was to assess the impact of larger than conventional amounts of 14 commonly used excipients on Biopharmaceutics Classification System (BCS) class…”
Get more information

Outcome of medical treatment of stricturing and penetrating Crohn's disease: A retrospective study by Samimi, Roxana, Flasar, Mark H., Kavic, Stephen, Tracy, Kathleen, Cross, Raymond K.

“…Background: Outcomes of medical treatment in patients with stricturing and penetrating Crohn's disease (CD) are not well characterized. Methods: Adults with…”
Get full text

Biological and Immunomodulator Use in Crohn's Disease in a Medicaid Population by Flasar, Mark H, Chao, Jingdong, Ozbay, A Burak, Skup, Martha, Lu, Mei, Cross, Raymond

“…Immunomodulator and biological use in African Americans (AA) with Crohn's disease (CD) has been reported to be lower than in whites (W); less data exist for…”
Get full text

Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center by Curtin, Bryan F, Zarbalian, Yousef, Flasar, Mark H, von Rosenvinge, Erik

“…To assess adherence with the the Society for Healthcare Epidemiology of America (SHEA)/ the Infectious Diseases Society of America (IDSA) guidelines for…”
Get full text

Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease by Patil, Seema A., Flasar, Mark H., Lin, Jay, Lingohr-Smith, Melissa, Skup, Martha, Wang, Song, Chao, Jingdong, Cross, Raymond K.

“…Background Radiation exposure from diagnostic imaging may increase cancer risk of Crohn’s disease (CD) patients, who are already at increased risk of certain…”
Get full text

Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease by Ghazi, Leyla J., Lydecker, Alison D., Patil, Seema A., Rustgi, Ankur, Cross, Raymond K., Flasar, Mark H.

“…Background The existing literature on racial differences in Crohn’s disease (CD) activity and quality of life (QOL) is limited and extrapolated from surrogate…”
Get full text

Characteristics of Clostridium difficile infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia by Shah, Kamini, Curtin, Bryan F, Chu, Christopher, Hwang, Daniel, Flasar, Mark H, von Rosenvinge, Erik

“…To evaluate factors associated with infection (CDI) and outcomes of CDI in the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) population…”
Get full text

Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs" by Vaithianathan, Soundarya, Haidar, Sam H, Zhang, Xinyuan, Jiang, Wenlei, Avon, Christopher, Dowling, Thomas C, Shao, Changxing, Kane, Maureen, Hoag, Stephen W, Flasar, Mark H, Ting, Tricia Y, Polli, James E

“…We previously concluded that 12 common excipients need not be qualitatively the same and quantitatively very similar to reference for Biopharmaceutics…”
Get more information

Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease by Patil, Seema A, Rustgi, Ankur, Quezada, Sandra M, Flasar, Mark H, Vandermeer, Fauzia, Cross, Raymond K

“…Diagnostic imaging is frequently used in Crohn's disease (CD) for diagnosis, evaluation of complications, and determination of response to treatment. Patients…”
Get full text

What is the need for comparative effectiveness studies in IBD? by Flasar, Mark H, Cross, Raymond K

“…Unlike traditional clinical trial research, Comparative Effectiveness Research seeks to determine what is 'best' for a typical patient when deciding between…”
Get more information

Acute abdominal pain by Flasar, Mark H, Goldberg, Eric

“…Because there are many causes of acute abdominal pain, a systematic approach by the evaluating physician is necessary to narrow the differential diagnosis. It…”
Get more information

Racial Differences in Disease Extent and Severity in Patients with Ulcerative Colitis: A Retrospective Cohort Study by Flasar, Mark H., Quezada, Sandra, Bijpuria, Priti, Cross, Raymond K.

“…Introduction Ulcerative colitis (UC) is increasing in African-Americans (AA). The objectives of this study were to assess disease extent and severity in UC by…”
Get full text

Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study by Flasar, Mark H., Johnson, Tamara, Roghmann, Mary‐Claire, Cross, Raymond K.

“…Background: Treatment disparities between African Americans (AA) and Caucasians exist in multiple diseases. There are limited studies in inflammatory bowel…”
Get full text

A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final Results by Zullow, Samantha, Flasar, Mark H, Greenberg, Deborah, Tracy, J Kathleen, Rustgi, Ankur, Cross, Raymond K

“…Adalimumab (Humira, AbbVie) has efficacy in treatment-naive and infliximab (Remicade, Janssen)-exposed patients with Crohn's disease (CD). An e-survey was sent…”
Get full text

Acute abdominal pain by Flasar, Mark H, Cross, Raymond, Goldberg, Eric

“…Acute abdominal pain is a complaint seen commonly in the outpatient setting that has a broad and often confusing differential diagnosis. Although many…”
Get more information

Current and future role of serogenomics in ulcerative colitis by Flasar, Mark H, Cross, Raymond K, Doman, David B

“…Ulcerative colitis (UC), a chronic inflammatory bowel disease, occurs in genetically susceptible individuals who mount inappropriate immune responses to…”
Get full text

Reply by Flasar, Mark H., Roghmann, Mary-Claire, Cross, Raymond K.

Get full text